Pralmorelin
http://dbpedia.org/resource/Pralmorelin an entity of type: Thing
Pralmorelin (INN) (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD).
rdf:langString
rdf:langString
Pralmorelin
xsd:integer
46946727
xsd:integer
1003125790
xsd:integer
45
xsd:integer
158861
xsd:integer
5293451
xsd:integer
55
xsd:integer
-6
xsd:integer
9
xsd:integer
6
xsd:integer
6852372
rdf:langString
Oral, intravenous
rdf:langString
C[C@H]N
xsd:integer
1
rdf:langString
HRNLPPBUBKMZMT-RDRUQFPZSA-N
rdf:langString
D-Alanyl-3--D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide
rdf:langString
E6S6E1F19M
xsd:integer
250
rdf:langString
Pralmorelin (INN) (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD). Pralmorelin is an orally-active, synthetic peptide drug, specifically, an analogue of met-enkephalin, with the amino acid sequence D-Ala-D-(β-naphthyl)-Ala-Trp-D-Phe-Lys-NH2. It acts as a ghrelin/growth hormone secretagogue receptor (GHSR) agonist, and was the first of this class of drugs to be introduced clinically. Acute administration of the drug markedly increases the levels of plasma growth hormone (GH) and reliably induces sensations of hunger and increases food intake in humans. Pralmorelin was also under investigation for the treatment of GHD and short stature (pituitary dwarfism), and made it to phase II clinical trials for these indications, but was ultimately never marketed for them. This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals.
xsd:integer
1092
xsd:nonNegativeInteger
7784
xsd:string
158861-67-7
xsd:string
E6S6E1F19M
xsd:string
6852372